IMAX · Imax Corp

The thesis

IMAX Corporation reported a record third quarter and a stronger 2026 outlook, which supports the case for durable premium-format demand, even though the shares fell 7.01% on the report. Dune: Part Three on 18 December 2026 and the 2027 box-office guidance due early next year settle whether that demand outlasts The Odyssey.

The 5 November 2026 report answered the question the previous note set. Management said on the call it expects to "significantly exceed" its $1.4 billion box-office guidance for 2026 and now targets an adjusted EBITDA (earnings before interest, taxes, depreciation and amortization) margin of approximately 50%, up from the mid-40% range. It kept its range of 160–175 system installations.

The narrative is maturing: the record summer is well known, and the shares closed at $48.13 on 5 November 2026 after a report that beat estimates, down from $52.31 on 22 October 2026. The fall reads as investors having paid for the quarter already and now waiting on 2027. A weekly close above the 52-week high of $56.33 before that guidance arrives would show this reading is wrong.

Bullish and bearish views on Imax Corp

The bull case on Imax Corp (IMAX), in brief: Results beat estimates by a wide margin. The bear case: The shares fell on a record report.

Bull case

• Results beat estimates by a wide margin. The company's 5 November 2026 release showed revenue of $174.6 million, up 64%, against a $168.5 million estimate cited in earnings headlines that day. The company put the figure at $1.58 without a $36.7 million tax benefit.
• Margins expanded sharply on record receipts. Adjusted EBITDA was $120.9 million in the third quarter, a 69.3% margin, and gross margin was 72.3%, according to the 5 November 2026 release. Box office was a record $712 million, 6.7% of the worldwide total on less than 1% of screens.
• Dune pre-sales trail only The Odyssey. Management said on 5 November 2026 that Dune: Part Three took more than $30 million in pre-sales in its first month, the second-highest in company history. Chief executive Rich Gelfond said the film should play "well into the new year," particularly on 70mm screens.
• China is improving into the holidays. Gelfond said on 5 November 2026 that China would finish "pretty much on budget for the year" after a weak first half. He cited a Maoyan estimate of $50 million to $65 million in IMAX receipts for the holiday period, when IMAX has an exclusive commitment with Disney for Avengers: Doomsday.
• Named analyst targets sit above the close. JP Morgan kept Overweight and raised its target to $58 on 23 October 2026, Wedbush's target is $60 (14 October 2026), Wells Fargo's is $55 (15 October 2026) and Goldman Sachs's is $50 (Neutral, 4 September 2026). All predate the report, and no post-report revision surfaced in coverage reviewed on 6 November 2026.
• The balance sheet carries little strain. IMAX reported $208 million of cash, net leverage of 0.2 times and $641 million of available liquidity at 30 September 2026. About $237 million of buyback authority remains through 30 June 2027, though the company repurchased no shares in the third quarter.

Bear case

• The shares fell on a record report. Motley Fool's transcript page showed the shares at $48.13 on the report, down 7.01% or $3.63. The close sits 14.6% below the 52-week high of $56.33, and the three-month change is a 6.0% decline.
• Guidance for 2027 is missing. Gelfond said on 5 November 2026 that guidance would come "sometime early next year" because the 2027 slate is not yet fully filled. Analysts pressed on post-Odyssey demand and pricing during the same call.
• One film carried the quarter. The Odyssey produced $538 million of the $712.1 million in third-quarter receipts, according to the 10-Q. Local-language films fell to $36.5 million, or 5% of IMAX box office, from $120.2 million and 33% a year earlier.
• Installations and backlog are lower. IMAX installed 32 systems in the third quarter against 38 a year earlier, and 89 in nine months against 95. Backlog was 409 systems at 30 September 2026 against 478 a year earlier and 421 at 30 June 2026. The release headline cites more than 100 signings this year, while its table through 30 September 2026 shows 79.
• Disney's rival format remains unresolved. Bloomberg reported on 8 October 2026 that Disney pitched Paramount and Universal on its large-screen brand. The Motley Fool transcript of the 5 November 2026 call records no discussion of it.

Price setup

The adjusted close on 5 November 2026 was $48.13, down from $52.31 on 22 October 2026 and $50.80 on 9 October 2026. The earlier note recorded an adjusted closing high of $56.05 on 25 September 2026, and the 52-week high is $56.33. The close now sits just above the $47 invalidation level in the previous note.

The 14-day relative strength index (RSI), a momentum gauge where readings near 30 mark heavy selling and near 70 heavy buying, was 41.4 on 5 November 2026, against 47.6 on 22 October 2026. That reading shows no overheating.

Crowding evidence is modest. The earnings date has passed, and the release shows no repurchases in the third quarter. A 23 July 2026 Benzinga headline linked that day's 11% jump partly to a short squeeze. Convertible notes are the main source of share-count change: diluted shares of 58.0 million in the third quarter included shares from the $250 million 0.75% notes due 2030.

Catalysts, next 30 days

No scheduled company report or major IMAX release was identified between 6 November 2026 and 6 December 2026. The case turns on these later events:

• 18 December 2026: Dune: Part Three opens, with a reported three-week domestic IMAX exclusivity. It is the first large test of premium demand after The Odyssey.
• 31 December 2026: Dune: Part Three opens in China, according to management's 5 November 2026 comments, after IMAX's Avengers: Doomsday holiday run there.
• Early 2027, no date set: Management gives 2027 box-office guidance. This is the first formal read on the year after the record.
• Chinese New Year 2027: Management said Wandering Earth 3 is planned for the period, a test of whether local-language receipts recover.

What would change the view

The case breaks if the outlook given on 5 November 2026 fails. Three results would show that: full-year installations under 160–175, a 2026 adjusted EBITDA margin under approximately 50%, or 2027 box-office guidance below the 2026 result. A major studio publicly committing films to Disney's large-screen label would damage the pricing argument.

Weak Dune: Part Three receipts after more than $30 million of pre-sales would also undercut the view that demand extends beyond one film. On price, a weekly close below $47 would end the thesis; that is the level that marked the late-summer advance. Sale speculation carries no weight in the case: CNBC reported on 28 August 2026 that no new bankers were engaged.

What it trades with

IMAX's results follow the film calendar more than the economy from quarter to quarter. Exhibitors such as AMC share exposure to the same releases; Benzinga reported on 20 August 2026 that the domestic box office had reached levels not seen since the pandemic. IMAX's royalty model and system sales make its earnings swing more sharply than ticket totals on a strong title, as the 69.3% third-quarter margin shows.

Disney is both a partner, through the Avengers: Doomsday commitment in China, and a potential rival through its format. Report days can move the shares apart from the market: Benzinga reported an 11% rise on 23 July 2026 while the Dow fell 450 points. With 91 countries and territories in the network, foreign-exchange rates and China's box office add separate sources of movement.